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mine the prevalence and to investigate independent risk factors for the development of CIN. METHODS
Between 2008 and 2014, all pre-hospital intubated major trauma patients with documented serum cre-
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analyzed. CIN was defined as a relative increase in SCr > 25% over the baseline value or an absolute SCr
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identify significant risk factors. A p value of < 0.01 was considered statistically significant and a p value
of 0.01-0.049 suggested evidence. RESULTS Of 284 analyzed patients, 41 (14%) met the criteria for CIN.
There is suggestive evidence that age and lactate level influenced the development of CIN. Six patients
(15%) had hemodialysis in the CIN-group and eight (3.3%) in the group without CIN. Complication and
mortality rate was higher in patients with CIN (71% vs. 56% and 32% vs. 23%, respectively). CIN was
not an independent risk factor for complications or mortality while controlling for age, gender, injury
severity score, and lactate level. The length of stay was not affected by CIN. CONCLUSION CIN oc-
curs frequently in trauma patients, but is not an independent risk factor for complications or mortality.
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Abstract
Background Contrast-induced nephropathy (CIN) has been well investigated in patients undergoing coronary angiography, 
but not in trauma patients. The main aim of this study was to determine the prevalence and to investigate independent risk 
factors for the development of CIN.
Methods Between 2008 and 2014, all pre-hospital intubated major trauma patients with documented serum creatinine levels 
(SCr) undergoing a contrast-enhanced whole-body CT at admission were retrospectively analyzed. CIN was defined as a 
relative increase in SCr > 25% over the baseline value or an absolute SCr increase of > 44 µmol/l within 72 h. Univariate 
and multivariable regression analyses were performed to identify significant risk factors. A p value of < 0.01 was considered 
statistically significant and a p value of 0.01–0.049 suggested evidence.
Results Of 284 analyzed patients, 41 (14%) met the criteria for CIN. There is suggestive evidence that age and lactate level 
influenced the development of CIN. Six patients (15%) had hemodialysis in the CIN-group and eight (3.3%) in the group 
without CIN. Complication and mortality rate was higher in patients with CIN (71% vs. 56% and 32% vs. 23%, respectively). 
CIN was not an independent risk factor for complications or mortality while controlling for age, gender, injury severity score, 
and lactate level. The length of stay was not affected by CIN.
Conclusion CIN occurs frequently in trauma patients, but is not an independent risk factor for complications or mortality. 
Therefore, contrast enhanced whole-body CT can safely be performed in trauma patients.
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Abbreviations
AKI  Acute kidney injury
CIN  Contrast-induced nephropathy
CPR  Cardiopulmonary resuscitation
FFP  Fresh frozen plasma
HES  Hydroxyl ethyl starches
ISS  Injury severity score
PCI  Percutaneous coronary intervention
RBC  Packed red blood cells
SCr  Serum creatinine levels
Background
Contrast-induced nephropathy (CIN) is characterized as an 
acute renal injury after the administration of intravascular 
iodinated radio-contrast medium in the absence of any other 
etiology [1]. Although the histological morphology of CIN 
is well characterized, the pathophysiologic mechanism of 
renal injury is still not clear. Most likely a combination of 
reduced renal perfusion, a reduction in tubular flow and/
or a direct tubular toxicity of contrast agent could lead to 
a decrease in glomerular filtration rate [1, 2]. CIN is com-
monly diagnosed by a 25% rise from baseline creatinine, or 
an absolute increase in creatinine of ≥ 44 µmol/l 24–48 h 
after administration of contrast [3–6].
The incidence of CIN varies from 0.6 to 2.3% in patients 
without any pre-existing renal impairment and rises up to 
30% in the presence of individual risk factors [7]. Advanced 
age, diabetes mellitus, pre-existing renal impairment, 
periprocedural intravascular volume depletion, congestive 
heart failure or concomitant use of other nephrotoxic drugs 
have been shown to increase the risk to develop CIN [2, 3, 
6, 8, 9]. CIN is the third leading cause of hospital acquired 
acute renal failure and associated with a significant increase 
in mortality [2, 3]. Hence, several strategies (e.g., pre- and 
post-hydration, administration of N-acetylcysteine) were 
proven to be more or less effective in the prevention of CIN 
[10], but are not feasible in every situation—especially in the 
treatment of severely injured patients. Further, the cause of 
creatinine increase in severely injured patients can be mul-
tifactorial (e.g., contrast-induced, hemorrhagic shock, blood 
transfusions, advanced age).
Whole-body computed tomography (CT) was shown to 
reduce mortality in polytraumatized patients, if integrated 
into early trauma care [11, 12]. Therefore, contrast enhanced 
whole-body CT is more and more routinely performed for 
the initial evaluation of severely injured patients. Although 
crucial in the care of traumatized patients, only a few studies 
focus on the incidence, the impact and the clinical impli-
cations of CIN in those patients and the risk factors are 
discussed controversially [13–15]. Finigan et al. could not 
identify any risk factor for CIN in their work [14] and Kim 
et al. reported age ≥ 65 years and ISS ≥ 25 to be indepen-
dently associated with acute renal injury, but not intravenous 
administered contrast medium [15]. The STARSurg Collab-
orative could not find any association between preoperative 
intravenous contrast administration and postoperative acute 
kidney injury after major gastrointestinal surgery [16].
To improve the understanding of CIN and its impact on 
severely injured patients, we conducted a retrospective anal-
ysis in our Level 1 trauma center. The main aim of this study 
was to determine prevalence of and to identify independent 
risk factors for CIN. Additionally, we assessed the clinical 
impact of CIN on the need of hemodialysis, complications 
rates, length of stay and mortality.
Materials and methods
This retrospective cohort study was approved by the local 
ethics committee (Kantonale Ethikkommission Zürich, 
Switzerland, KEK ZH No. 2011-0382) and adheres to the 
Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) recommendations for cohort stud-
ies [17, 18].
Study design and participants
We included all adult, pre-hospital intubated trauma patients 
admitted to the emergency department of the University 
Hospital Zurich between October 2008 and December 2014 
who received a contrast enhanced whole-body CT directly 
on arrival (n = 350). Patients with missing initial or follow-
up (within 72 h) serum creatinine levels (sCr) were excluded 
from the study (n = 66). The whole-body CT algorithm of 
the University Hospital Zurich was changed at the end of 
2014. To avoid a potential study bias, we limited our analysis 
to the above-mentioned period. A total of 284 patients met 
inclusion criteria and were further analyzed.
Setting
Severely injured patients are admitted to the resuscitation 
area of our level I trauma center. In the division of trauma 
surgery, a standardized clinical approach is provided in 
the resuscitation area. The standard diagnostic algorithm 
includes a native head and neck CT followed by a primary 
contrast enhanced (100 ml iso-osmolar, non-ionic iodinated 
contrast material [300 mg iodine per millilitre, iopromide 
 (Ultravist®; Bayer Healthcare, Leverkusen, Germany)] fol-
lowed by a saline flush of 30 ml [19]) chest and abdomen 
CT during the whole study period. After initial stabilization 
in collaboration with the anesthesiologists, damage control 
or early total care surgery is performed [20], and patients 
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are subsequently transferred to the intensive care unit for 
further treatment.
Variables and data collection
Demographics (age, gender comorbidities), injury severity 
score (ISS), complications, length of stay (LOS), need for 
hemodialysis, and death were extracted from the electronic 
medical record (KISIM, Cistec AG, Zürich, Switzerland). 
Extracted laboratory values included hemoglobin and fibrino-
gen level at admission (g/l), initial base excess (mmol/l) as well 
as serum lactate (mmol/l), initial and follow-up SCr levels. In 
addition, the following data were extracted from the anesthesia 
records until the admission to the ICU: volume of resuscitation 
fluids like crystalloid solution (in liters), the use of allogeneic 
blood products such as packed red blood cells (RBC, in num-
bers), fresh frozen plasma (FFP, yes/no), platelet concentrates 
(yes/no) and the use of fibrinogen (yes/no).
Contrast-induced nephropathy (CIN) was defined as a rela-
tive increase in serum creatinine > 25% of the baseline value or 
an absolute increase > 44 µmol/l within 72 h [6].
Complications were defined as the presence of acute delir-
ium, myocardial infarction, deep vein thrombosis, pulmonary 
embolism, urinary tract infection, surgical site infection or 
complications such as pneumonia, sepsis, SIRS, cerebrovas-
cular incidents or coagulopathy during the hospitalization [21].
Study endpoints
The main goal of this study was to determine prevalence of 
and to identify independent risk factors for CIN.
Additionally, we assessed the clinical impact of CIN on 
the need of hemodialysis, complications rates, length of stay 
and mortality.
Statistical analyses
Categorical data are reported as frequency and percent and 
numerical data as mean ± standard deviation (SD). The Chi‐
square and Fisher’s exact test were used to compare categorical 
data and the Mann–Whitney U-test for numerical data. Age, 
gender, Injury Severity Score for anatomic severity, and lactate 
level for physiologic severity were entered in multiple regres-
sion analysis as suggested by Haider et al. (“Bare minimum”) 
[22]. In addition, CIN was forced into the models where appli-
cable. Model fit was assessed using the Hosmer–Lemeshow 
test. The Glasgow Coma Scale and need for ventilator use were 
not used in these models since all patients were intubated at 
arrival. Lactate level was skewed to the right and therefore 
logarithmically transformed. All statistical analyses were per-
formed by IBM SPSS Statistics 23 (IBM Corp., Armonk, NY, 
USA). Missing values were not entered into the analysis. A 
p value of < 0.01 was considered statistically significant, a p 
value of 0.01–0.049 showed suggestive evidence [23].
Results
Prevalence of and independent risk factors for CIN
Prevalence of CIN was present in 41 out of 284 patients 
(14%) (Table 1). Patients suffering from CIN had a signifi-
cant lower hemoglobin level at admission (p = 0.002), were 
on average 9 years older (p = 0.019), had a slightly lower 
creatinine (p = 0.026) and lactate level (p = 0.036) at admis-
sion. Systolic blood pressure at admission was similar in 
both groups (p = 0.094). Patients with CIN received slightly 
more crystalloids (p = 0.042), fibrinogen (p = 0.027), and 
red blood cells (p = 0.017). In multivariate analysis, there 
Table 1  Summary of patient characteristics between the CIN and no 
CIN group
CIN contrast-induced nephropathy
No CIN CIN p value
n = 243 (86%) n = 41 (14%)
Age (years) 46 ± 22 55 ± 23 0.019
Gender (male) 192 (79%) 29 (71%) 0.238
Comorbidities 145 (60%) 25 (61%) 0.875
Blunt trauma 235 (97%) 40 (98%) 0.673
Injury Severity Score 28 ± 17 30 ± 16 0.296
AIS head 3.1 ± 1.8 3.2 ± 1.8 0.733
AIS face 0.7 ± 1.1 0.6 ± 1.2 0.765
AIS chest 1.5 ± 1.8 1.6 ± 1.7 0.771
AIS abdomen 0.6 ± 1.2 0.7 ± 1.3 0.719
AIS extremity 1.2 ± 1.4 1.5 ± 1.6 0.316
AIS integument 0.9 ± 0.9 0.9 ± 0.8 0.961
Heart rate at admission 
(bpm)
88 ± 24 86 ± 22 0.513
Systolic blood pressure at 
admission (mmHg)
121 ± 28 112 ± 21 0.094
Serum creatinine (µmol/l) 81 ± 29 73 ± 26 0.026
Hemoglobin (g/l) 11.7 ± 2.4 10.4 ± 2.7 0.002
Fibrinogen (g/l) 2.1 ± 0.7 2.2 ± 1.1 0.645
Lactate level (mmol/l) 2.7 ± 2.6 2.0 ± 1.7 0.036
Base excess (mmol/l) − 4.2 ± 4.6 − 4.2 ± 4.5 0.800
Crystalloid (l) 2.2 ± 2.9 2.6 ± 2.4 0.042
Red blood cells (n) 1.3 ± 4.9 2.3 ± 4.7 0.017
Fresh frozen plasma 13 (5.4%) 4 (9.8%) 0.287
Platelets 18 (7.5%) 7(17%) 0.069
Fibrinogen 80 (33%) 21 (51%) 0.027
Hemodialysis 8 (3.3%) 6 (15%) 0.008
Complications 136 (56%) 29 (71%) 0.076
Length of stay (days) 14 ± 13 18 ± 20 0.407
Mortality 55 (23%) 13 (32%) 0.208
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is suggestive evidence that age (p = 0.035) and lactate level 
(p = 0.034) influenced the development of CIN (R2 = 0.071) 
(Table 2).
Hemodialysis
Hemodialysis was necessary in 6 out of 41 CIN patients 
(15%) and 8 out of 243 patients (3.3%) without CIN 
(p = 0.008) (Table  1). The use of fresh frozen plasma 
(p = 0.006) and platelets (p = 0.004) were significantly, 
Injury Severity Score (p = 0.034), amount of infused crys-
talloids (p = 0.012), numbers of RBC (p = 0.040) and use of 
fibrinogen (p = 0.023) were slightly associated with hemo-
dialysis. The low numbers of hemodialysis did not allow 
multivariate analysis.
Complications
Complications during hospital stay occurred in 29 CIN 
patients (71%) and in 136 patients (56%) without CIN 
(p = 0.076). Pneumonia (10/29), wound infections (4/29), 
deep vein thrombosis (4/29) and sepsis (3/29) were the most 
common complications in patients suffering from CIN. 
Injury Severity Score (p < 0.001), hemoglobin (p = 0.001) 
and fibrinogen at admission (p = 0.002), base excess 
(p = 0.001), amount of crystalloids (p < 0.001), numbers 
of RBC (p = 0.001), use of fibrinogen (p < 0.001) and FFP 
(p = 0.008) were significantly associated with the develop-
ment of complications. However, preexisting comorbidities 
(p = 0.024) were only slightly associated with the develop-
ment of complications. In multivariate analysis, ISS was 
a risk factor for complications (p = 0.004), but not CIN 
(R2 = 0.083) (Table 3).
Length of hospital stay
The length of hospital stay was not affected by CIN (18 ± 20 
with vs. 14 ± 13 days without CIN, p = 0.407) (Table 1).
Mortality
In-hospital mortality was 32% in patients with and 23% in 
patients without CIN (p = 0.208) (Table 1). Age (p < 0.001), 
comorbidities (p < 0.001), ISS (p < 0.001), hemoglobin at 
admission (p < 0.001), base excess (p < 0.001), amount 
of RBC (p = 0.006), use of FFP (p = 0.007) or platelets 
(p < 0.001) were significantly, lactate level (p = 0.044) 
slightly associated with death. CIN was not an independ-
ent risk factor for mortality (R2 = 0.435). However, age 
(p < 0.001) and a higher ISS (p < 0.001) were independent 
predictors for mortality (Table 4).
Discussion
Most of the research about CIN has been performed in 
patients undergoing percutaneous coronary interventions 
(PCI). To our knowledge, this study is one of few studies 
investigating CIN in the population of severe trauma and 
the only one in an European trauma center [24]. We thus 
intentionally focused on severely injured and already intu-
bated patients. Due to our standardized diagnostic approach, 
they are most likely to undergo immediate contrast enhanced 
Table 2  Risk factors for CIN
Multivariable logistic regression analysis with following explanatory 
variables: age, gender, Injury Severity Score for anatomic severity, 
and logarithmically transformed lactate level for physiologic severity
CI confidence interval, OR odds ratio
OR 95% CI p value
Age (years) 1.017 1.001 1.033 0.035
Injury Severity Score 1.008 0.988 1.029 0.430
Gender (Male) 0.806 0.370 1.760 0.589
Lactate level (logarithmic) 0.269 0.080 0.906 0.034
Table 3  Risk factors for any complications
Bold values indicate significant values
Multivariable logistic regression analysis with following explanatory 
variables: age, gender, Injury Severity Score for anatomic severity, 
and logarithmically transformed lactate level for physiologic severity
CI confidence interval, CIN contrast-induced nephropathy, OR odds 
ratio
OR 95% CI p value
CIN 2.029 0.960 4.291 0.064
Lactate level (logarithmic) 2.027 0.867 4.737 0.103
Injury Severity Score 1.025 1.008 1.042 0.004
Age (years) 0.998 0.986 1.010 0.730
Gender (male) 0.939 0.511 1.727 0.840
Table 4  Risk factors for mortality
Bold values indicate significant values
Multivariable logistic regression analysis with following explanatory 
variables: age, gender, Injury Severity Score for anatomic severity, 
and logarithmically transformed lactate level for physiologic severity
CI confidence interval, CIN contrast-induced nephropathy, OR odds ratio
OR 95% CI p value
CIN 1.192 0.480 2.962 0.706
Injury Severity Score 1.098 1.066 1.130 < 0.001
Lactate level (logarithmic) 1.618 0.533 4.916 0.396
Gender (male) 1.051 0.446 2.480 0.909
Age (years) 1.030 1.013 1.047 < 0.001
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whole-body CT regardless of any pre-existing medical con-
dition (e.g., renal insufficiency, diabetes mellitus), allergies 
or specific injuries. The prevalence of CIN was 14% in this 
population and we could identify lactate level as well as 
age as independent risk factors. Patients suffering from CIN 
were more likely to need hemodialysis (4.7 times), but the 
complication and mortality rate as well as length of hospital 
stay were not significantly affected by CIN.
The prevalence of CIN was 14% in our study population, 
which is slightly higher than described by other authors. 
Comparable studies found a prevalence ranging from 2.1 
to 5.1% [3, 4, 13, 25]. Other studies in non-trauma patients 
reported a prevalence of 0.8–4.7% [26, 27]. The reason for 
our higher prevalence is probably due to our cohort compro-
mising only severely injured patients. Age was a suggestive 
risk factor for CIN in our cohort. This is comprehensible 
and in accordance with other studies [28]. A lower lactate 
level was also a suggestive risk factor. This seems coun-
terintuitive. However, the authors interpret this due to the 
increased need of volume and transfusions of these patients, 
as allogenic blood products are associated with a number 
of harmful side effects [29, 30]. The question remains if 
an aggressive volume and transfusion management really 
increases the risk of CIN. Low hemoglobin level on admis-
sion was significantly associated with nephropathy, as also 
described by Xu and colleagues in patients undergoing coro-
nary angioplasty or PCI [31]. Other authors did not find 
anemia to be a risk factor for CIN, at least in cardiac patients 
[32, 33]. Banda et al. found that anemia was not a risk factor 
for CIN, but CIN in combination with low hemoglobin levels 
doubled the mortality in their population [34]. Likewise, 
there is suggestive evidence that the amount of transfused 
red blood cell units is associated with CIN. There is pos-
sibly an exponentiating effect. Red blood cell transfusion 
of itself is a clear risk factor for acute kidney injury; in a 
meta-analysis by Karkouti et al., every unit of red blood 
cells increased the risk for acute kidney injury by 10–20% 
in cardiac surgery patients [35].
The development of nephropathy in polytraumatized 
patients is an intricate process. Vassiliu and his colleges 
analyzed trauma patients after angiographic embolization 
and found that age, hypovolemia, renal trauma and severe 
injuries were no risk factors for CIN in their population [36]. 
In contrast, Matsushima et al. found a higher ISS to be an 
independent risk factor for developing CIN [37]. The litera-
ture shows several strategies to prevent CIN. Because of the 
feasibility in this setting and the lack of doubtless proof [10] 
no routine administration of n-acetylcysteine was performed 
in our hospital.
The hemodialysis rate was 15%. Other studies found 
0.3–7% of patients requiring hemodialysis after the admin-
istration of contrast agents [4, 38]. The presence of CIN 
significantly increased the risk for hemodialysis in our 
population. One study found a higher rate of hemodialy-
sis in patients developing CIN but was not able to identify 
CIN as a significant risk factor [39]. In our cohort, a higher 
ISS, an increased amount of crystalloids, allogeneic blood 
transfusion and procoagulant agents were associated with an 
increased need for hemodialysis. As with the nephropathy, 
the question remains about the causality.
Severely injured patients had a high complication rate, 
independent of CIN. Most of these complications were 
infections (pneumonia, cystitis) or wound complications 
(seroma, surgical site infection). The ISS was the most 
important risk factor for complications, which is consist-
ent with the results of many other trauma studies. Patients 
suffering from CIN had not a higher risk of experiencing 
complication during their hospitalization.
Age and ISS influenced the mortality rate in our study, 
but not CIN. Other studies found an increased 1-year mor-
tality in patients suffering from CIN after cardiac inter-
ventions. But it remains unclear if this due to CIN or the 
present underlying conditions and comorbidities, asking 
for the contrast-enhanced CT [40, 41].
There are some limitations to this study. Due to the 
retrospective design of our study we can only deduct asso-
ciation and not causation. There may be some confound-
ers which we cannot detect and correct retrospectively. 
The whole-body CT algorithm of the University Hospi-
tal Zurich was changed at the end of 2014. To avoid a 
potential study bias, we limited our analysis to the period 
from 2008 to the end of 2014. We intentionally focused 
on prehospital intubated patients due to our pre-defined, 
consistent diagnostic approach. All intubated trauma 
patients underwent immediately contrast-enhanced whole-
body CT regardless of the injury pattern; the presence of 
a known renal impairment, allergies, or SCr levels was 
never known prior to the CT scan in these patients. Not 
intubated trauma patients may have undergone a different 
diagnostic approach due to the possibility to take a medi-
cal history at admission and to consider contraindication to 
perform a contrast enhanced whole-body CT scan. Avail-
able long-term data were incomplete and did not allow 
us to perform follow-up examinations to detect persistent 
renal failure or injury. Last, our analyzed patient cohort 
was not big enough to control for more than five factors in 
multivariate analysis.
We conclude that even in severely injured patients it is 
safe to perform contrast enhanced whole-body CT with-
out further harming these patients. Even if CIN occurs, a 
benign course is likely and the patient’s outcome, espe-
cially mortality and length of hospital stay are not affected. 
Further research is needed to investigate the effect of fluid 
and blood management on the development of CIN and the 
long-term outcome of patients affected by CIN.
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